AIDS 2024: Ten early reports
12 August 2024. Related: Conference reports, Antiretrovirals, World AIDS 25 Munich 2024.
Early reports from the conference will be added below as they are posted.
- Research to watch out for at AIDS 2024
- Lenacapavir as PrEP is “beyond wonderful” but PURPOSE 1 study tells us so much more
- Lenacapavir could be produced for $40 a year: 1000-fold lower than current US price for treating MDR HIV
- Five days on two days off: Biktarvy in pilot FOTO study
- Sub-cutaneous formulation of long-acting CAB/RPV discontinued
- New community call to challenge social settings that drive HIV-related stigma
- UNAIDS report: The urgency of now – AIDS at a crossroads.
- Switching to daily oral bictegravir and lenacapavir dual therapy to simplify ART in ARTISTRY-1 study